Literature DB >> 24121275

The MYB proto-oncogene suppresses monocytic differentiation of acute myeloid leukemia cells via transcriptional activation of its target gene GFI1.

L Zhao1, P Ye2, T J Gonda2.   

Abstract

The MYB gene is a master regulator of hematopoiesis and contributes to leukemogenesis in several species including humans. Although it is clear that MYB can promote proliferation, suppress apoptosis and block differentiation, the identities of the MYB target genes that mediate these effects have only been partially elucidated. Several studies, including our own, have collectively identified substantial numbers of MYB target genes, including candidates for each of these activities; however, functional validation, particularly in the case of differentiation suppression, has lagged well behind. Here we show that GFI1, which encodes an important regulator of hematopoietic stem cell (HSC) function and granulocytic differentiation, is a direct target of MYB in myeloid leukemia cells. Chromatin immunoprecipitation and reporter studies identified a functional MYB-binding site in the promoter region of GFI, whereas ectopic expression and small hairpin RNA-mediated knockdown of MYB resulted in concomitant increases and decreases, respectively, in GFI1 expression. We also demonstrate that GFI1, like MYB, can block the induced monocytic differentiation of a human acute myeloid leukemia cell line, and most importantly, that GFI1 is essential for MYB's ability to block monocytic differentiation. Thus, we have identified a target of MYB that is a likely mediator of its myeloid differentiation-blocking activity, and which may also be involved in MYB's activities in regulating normal HSC function and myeloid differentiation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24121275     DOI: 10.1038/onc.2013.419

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

1.  TCEA1 regulates the proliferative potential of mouse myeloid cells.

Authors:  Taomei Yang; Haoran Cui; Mingxin Wen; Johannes Zuber; Scott C Kogan; Guangwei Wei
Journal:  Exp Cell Res       Date:  2018-07-25       Impact factor: 3.905

2.  DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia.

Authors:  Eric Haines; Yuki Nishida; Michael Andreeff; Lyubomir T Vassilev; Michael I Carr; Rafael Heinz Montoya; Lauren B Ostermann; Weiguo Zhang; Frank T Zenke; Andree Blaukat
Journal:  Sci Rep       Date:  2021-06-09       Impact factor: 4.379

3.  METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification.

Authors:  Hengyou Weng; Huilin Huang; Huizhe Wu; Xi Qin; Boxuan Simen Zhao; Lei Dong; Hailing Shi; Jennifer Skibbe; Chao Shen; Chao Hu; Yue Sheng; Yungui Wang; Mark Wunderlich; Bin Zhang; Louis C Dore; Rui Su; Xiaolan Deng; Kyle Ferchen; Chenying Li; Miao Sun; Zhike Lu; Xi Jiang; Guido Marcucci; James C Mulloy; Jianhua Yang; Zhijian Qian; Minjie Wei; Chuan He; Jianjun Chen
Journal:  Cell Stem Cell       Date:  2017-12-28       Impact factor: 25.269

4.  c-Myb Binding Sites in Haematopoietic Chromatin Landscapes.

Authors:  Mads Bengtsen; Kjetil Klepper; Sveinung Gundersen; Ignacio Cuervo; Finn Drabløs; Eivind Hovig; Geir Kjetil Sandve; Odd Stokke Gabrielsen; Ragnhild Eskeland
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

5.  Inhibition of c-MYC with involvement of ERK/JNK/MAPK and AKT pathways as a novel mechanism for shikonin and its derivatives in killing leukemia cells.

Authors:  Qiaoli Zhao; Andreana N Assimopoulou; Sabine M Klauck; Harilaos Damianakos; Ioanna Chinou; Nadine Kretschmer; José-Luis Rios; Vassilios P Papageorgiou; Rudolf Bauer; Thomas Efferth
Journal:  Oncotarget       Date:  2015-11-17

6.  Peptidomimetic blockade of MYB in acute myeloid leukemia.

Authors:  Kavitha Ramaswamy; Lauren Forbes; Gerard Minuesa; Tatyana Gindin; Fiona Brown; Michael G Kharas; Andrei V Krivtsov; Scott A Armstrong; Eric Still; Elisa de Stanchina; Birgit Knoechel; Richard Koche; Alex Kentsis
Journal:  Nat Commun       Date:  2018-01-09       Impact factor: 14.919

7.  Myb expression is critical for myeloid leukemia development induced by Setbp1 activation.

Authors:  Nhu Nguyen; Bandana A Vishwakarma; Kevin Oakley; Yufen Han; Bartlomiej Przychodzen; Jaroslaw P Maciejewski; Yang Du
Journal:  Oncotarget       Date:  2016-12-27

8.  MYB induces the expression of the oncogenic corepressor SKI in acute myeloid leukemia.

Authors:  Miriam Frech; Sabine Teichler; Christine Feld; Caroline Bouchard; Hannah Berberich; Katharina Sorg; Marco Mernberger; Lars Bullinger; Uta-Maria Bauer; Andreas Neubauer
Journal:  Oncotarget       Date:  2018-04-27

9.  C/EBPβ is a MYB- and p300-cooperating pro-leukemogenic factor and promising drug target in acute myeloid leukemia.

Authors:  Maria V Yusenko; Amke Trentmann; Debora A Casolari; Luca Abdel Ghani; Mairin Lenz; Melanie Horn; Wolfgang Dörner; Stefan Klempnauer; Henning D Mootz; Maria Francisca Arteaga; Jan-Henrik Mikesch; Richard J D'Andrea; Thomas J Gonda; Carsten Müller-Tidow; Thomas J Schmidt; Karl-Heinz Klempnauer
Journal:  Oncogene       Date:  2021-05-06       Impact factor: 9.867

Review 10.  SETBP1 dysregulation in congenital disorders and myeloid neoplasms.

Authors:  Nicoletta Coccaro; Giuseppina Tota; Antonella Zagaria; Luisa Anelli; Giorgina Specchia; Francesco Albano
Journal:  Oncotarget       Date:  2017-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.